Economics, not science, thwarts embryonic stem cell therapy
Sunday, November 20, 2011 - 23:00
in Health & Medicine
Geron Corp. pulls the plug on its ambitious effort to reverse spinal damage and will focus instead on financially less risky cancer drugs. For patients paralyzed by spinal cord injuries, Geron Corp.'s stem cell research was the shining hope.